DCP
REGN icon

DSM Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

DSM Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-374,203
Closed -$154M – 54
2019
Q1 		$154M Buy
374,203
+2,823
+0.8% +$1.16M 2.27% 18
2018
Q4 		$139M Buy
371,380
+50,410
+16% +$18.5M 2.39% 18
2018
Q3 		$130M Buy
320,970
+83,276
+35% +$31.7M 1.93% 20
2018
Q2 		$82M Sell
237,694
-47,692
-17% -$14.9M 1.25% 25
2018
Q1 		$98.3M Sell
285,386
-849,954
-75% -$296M 1.36% 24
2017
Q4 		$427M Buy
1,135,340
+73,889
+7% +$29.9M 5.94% 4
2017
Q3 		$475M Sell
1,061,451
-21,642
-2% -$10.3M 6.73% 3
2017
Q2 		$532M Buy
1,083,093
+474,050
+78% +$207M 7.89% 3
2017
Q1 		$236M Buy
609,043
+258,212
+74% +$95.7M 3.85% 10
2016
Q4 		$129M Buy
350,831
+123,883
+55% +$47.1M 2.23% 21
2016
Q3 		$91.2M Buy
226,948
+51,333
+29% +$20.6M 1.47% 28
2016
Q2 		$61.3M Sell
175,615
-8,328
-5% -$3.21M 1.06% 30
2016
Q1 		$66.3M Buy
183,943
+3,310
+2% +$1.36M 1.09% 31
2015
Q4 		$98.1M Buy
180,633
+22,673
+14% +$12.3M 1.54% 29
2015
Q3 		$73.5M Sell
157,960
-101,859
-39% -$54.7M 1.37% 30
2015
Q2 		$133M Sell
259,819
-195,907
-43% -$95.6M 2.26% 25
2015
Q1 		$206M Sell
455,726
-61,213
-12% -$25.9M 3.53% 11
2014
Q4 		$212M Sell
516,939
-3,308
-0.6% -$1.3M 3.91% 7
2014
Q3 		$188M Sell
520,247
-11,683
-2% -$3.92M 3.72% 8
2014
Q2 		$150M Buy
531,930
+48,663
+10% +$14.4M 3.05% 15
2014
Q1 		$145M Buy
483,267
+120,154
+33% +$37M 3.03% 17
2013
Q4 		$99.9M Buy
+363,113
New +$104M 2% 25

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

DSM Capital Partners's REGN Position: Q2 2019 in Review

DSM Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2019, closing a stake of 374,203 shares — an estimated $154M sold.

DSM Capital Partners first reported a position in REGN in Q4 2013 and held it in 22 quarters. The position peaked at $532M in Q2 2017. 658 funds tracked by Wall St. Rank hold REGN as of Q2 2019.

  • DSM Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • DSM Capital Partners sold 374,203 Regeneron Pharmaceuticals shares in Q2 2019, an estimated $154M.
  • DSM Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2013 and held it in 22 quarters.
  • DSM Capital Partners's Regeneron Pharmaceuticals position peaked at $532M in Q2 2017.
  • 658 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2019.

Based on DSM Capital Partners's 13F filing for Q2 2019, filed 14 Aug 2019.